Search company, investor...

Synageva BioPharma

synageva.com

Founded Year

1996

Stage

Acq - P2P | Acquired

Total Raised

$93.1M

Valuation

$0000 

Revenue

$0000 

About Synageva BioPharma

Synageva BioPharma is dedicated to discovering, developing and delivering medicines for patients with rare diseases and unmet medical need. The Company has developed a pipeline of therapeutic products for under-served populations and has assembled a team with a proven record of bringing orphan therapies to patients.

Headquarters Location

33 Hayden Ave.

Lexington, Massachusetts, 02421,

United States

781-357-9900

Missing: Synageva BioPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Synageva BioPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Synageva BioPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Synageva BioPharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Synageva BioPharma Patents

Synageva BioPharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/11/2015

1/1/2019

Rare diseases, Hepatology, Autosomal recessive disorders, Syndromes, Diseases of liver

Grant

Application Date

9/11/2015

Grant Date

1/1/2019

Title

Related Topics

Rare diseases, Hepatology, Autosomal recessive disorders, Syndromes, Diseases of liver

Status

Grant

Latest Synageva BioPharma News

Terns appoints Radhika Tripuraneni to its Board of Directors

Aug 1, 2022

Radhika Tripuraneni Terns Pharmaceuticals, Inc. (Terns), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development, a statement said. “Terns’ approach of discovering and developing next-generation small molecules for clinically de-risked targets in indications with significant unmet need is an exciting strategy,” said Dr. Tripuraneni. “I am thrilled to join this accomplished team and look forward to working with the board and the management team to advance three clinically validated mechanisms in three indications with large, unmet needs towards three important clinical readouts across NASH, oncology and obesity.” “Dr. Tripuraneni has a breadth of scientific, medical and drug development expertise and I am pleased to have her join our board of directors where she will provide valuable support to our mission,” said Sen Sundaram, Chief Executive Officer of Terns. “Her strategic and operational experience in bringing important treatments to patients positions her well to guide Terns towards generating meaningful clinical data across several indications in the coming years.” Dr. Tripuraneni has served as Prothena’s Chief Development Officer since 2018 and is a seasoned biotech executive. Prior to joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs and Chief of Staff to the Chief Medical Officer of MyoKardia Inc. She was Vice President, Medical Affairs at Synageva BioPharma Corp. and then Alexion Pharmaceuticals Inc., which acquired Synageva. Earlier in her career, Dr. Tripuraneni held various medical director and business development positions at Gilead Sciences, Inc. and Genzyme Corporation, and worked at Summer Street Research Partners, a healthcare equity research firm. Dr. Tripuraneni earned her Bachelor’s degrees in business administration and liberal arts and her M.D. from the University of Missouri, and her Master’s in Public Health from Harvard University. She did her clinical training in general surgery at Harvard – Beth Israel Deaconess Medical Center. Ashish Nain

Synageva BioPharma Frequently Asked Questions (FAQ)

  • When was Synageva BioPharma founded?

    Synageva BioPharma was founded in 1996.

  • Where is Synageva BioPharma's headquarters?

    Synageva BioPharma's headquarters is located at 33 Hayden Ave., Lexington.

  • What is Synageva BioPharma's latest funding round?

    Synageva BioPharma's latest funding round is Acq - P2P.

  • How much did Synageva BioPharma raise?

    Synageva BioPharma raised a total of $93.1M.

  • Who are the investors of Synageva BioPharma?

    Investors of Synageva BioPharma include Alexion, AstraZeneca Rare Disease, Trimeris, Tullis Health Investors, Baker Brothers Investments, Yasuda Enterprise Development and 11 more.

  • Who are Synageva BioPharma's competitors?

    Competitors of Synageva BioPharma include Perseus Proteomics, Banyan Biomarkers, Viridian Therapeutics, Molecular Templates, Bicycle Therapeutics and 10 more.

Compare Synageva BioPharma to Competitors

C
CoPlex Therapeutics

CoPlex Therapeutics is focused on R&D to provide neuroprotection from dementia caused by a protein complex that accumulates in the central nervous system and begins the cascade effect that leads to dementia including Alzheimer's.

A
Angiogenix

Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.

NellOne Therapeutics Logo
NellOne Therapeutics

NellOne Therapeutics is a regenerative-medicine spinout of the U.S. Department of Energy's Oak Ridge National Laboratory (ORNL). The start-up, in the proof-of-efficacy stage, is dedicated to exploring the creation of protein therapeutics for their potential in restoring tissue mass andfunction in patients recovering from heart attacks. Current therapeutic approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function. General Partner Tracy Warren is acting CEO and a member of the Board of Directors. (See deal announcement.)

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

A
ArBlast

ArBlast is ArBlast was established in December 2005. Using the collagen sheet obtained by processing the human amniotic membrane, it is a regenerative medicine venture that regenerates various tissues.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.